Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 17, 2026
Section 16 reporting ended · disclosed 2026-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,750 |
Reported balance
After 2026-02-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 18,750 · Balance 18,750 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 112,500 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Grant · Acquired 112,500 · Balance 112,500 F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 740,188 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 740,188 F2: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 17, 2026 19:52 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001967150-26-000004 · form4-02182026_120203.xml · derivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2036-02-12 F3 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 19:52 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001967150-26-000004 · form4-02182026_120203.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 18:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $29.04 | $145,219.00 |
DisclosureSEC source: 0001967150-26-000003 · form4-02102026_110257.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 740,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 17:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 14,509 | $26.90 | $390,284.85 |
DisclosureSEC source: 0001967150-26-000002 · form4-01222026_100144.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 745,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 17:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,491 | $26.37 | $144,814.14 |
DisclosureSEC source: 0001967150-26-000002 · form4-01222026_100144.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 759,697 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 17:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 50,000 | $29.13 | $1,456,715.00 |
DisclosureSEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 765,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 17:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 41,198 | $24.90 | $1,025,863.16 |
DisclosureSEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 815,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 17:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 33,802 | $24.92 | $842,474.29 |
DisclosureSEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 856,386 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 17:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,500 | $20.13 | $150,961.50 |
DisclosureSEC source: 0001967150-26-000001 · form4-01122026_100153.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 890,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 18:45 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $16.84 | $84,206.00 |
DisclosureSEC source: 0001967150-25-000008 · form4-12232025_111217.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 897,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.605 to $17.115. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 17:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 492 | $23.09 | $11,360.77 |
DisclosureSEC source: 0001967150-25-000007 · form4-11212025_101158.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 902,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $23.045 to $23.165. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 17:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,008 | $22.30 | $267,794.01 |
DisclosureSEC source: 0001967150-25-000007 · form4-11212025_101158.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 903,180 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.035 to $23.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 19:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $22.08 | $276,025.00 |
DisclosureSEC source: 0001967150-25-000006 · form4-10222025_111054.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 915,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.285 to $22.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 17:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,000 | $20.25 | $81,005.20 |
DisclosureSEC source: 0001967150-25-000005 · form4-09302025_090907.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 927,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.015 to $20.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| September 23, 2025 Filed Sep 25, 2025 19:44 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,500 | $20.03 | $30,045.00 |
DisclosureSEC source: 0001967150-25-000004 · form4-09252025_110942.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 931,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 17:14 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,130 | $20.02 | $42,634.08 |
DisclosureSEC source: 0001967150-25-000003 · form4-09232025_090918.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 933,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 17:14 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,870 | $19.11 | $93,063.27 |
DisclosureSEC source: 0001967150-25-000003 · form4-09232025_090918.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 935,318 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2025 Filed Aug 21, 2025 18:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,500 | $20.01 | $150,099.00 |
DisclosureSEC source: 0001415889-25-022648 · form4-08212025_100834.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 940,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 18:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $19.62 | $98,117.50 |
DisclosureSEC source: 0001415889-25-022648 · form4-08212025_100834.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 947,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.0925 to $20.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 18:52 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 576 | $22.90 | $13,187.75 |
DisclosureSEC source: 0001415889-25-020206 · form4-07232025_100717.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 952,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.81 to $23.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 18:52 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 11,924 | $22.26 | $265,458.05 |
DisclosureSEC source: 0001415889-25-020206 · form4-07232025_100717.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 953,264 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.81 to $22.805. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 17:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $21.40 | $267,457.50 |
DisclosureSEC source: 0001415889-25-018116 · form4-06242025_090617.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 965,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.1228 to $22.0249. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,500 | $20.03 | $150,219.75 |
DisclosureSEC source: 0001415889-25-015787 · form4-06052025_080654.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 977,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| May 19, 2025 Filed May 21, 2025 18:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $16.31 | $81,533.50 |
DisclosureSEC source: 0001415889-25-013993 · form4-05212025_100540.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 985,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| May 02, 2025 Filed May 5, 2025 18:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,470 | $20.01 | $49,424.45 |
DisclosureSEC source: 0001415889-25-012031 · form4-05052025_100540.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 990,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,030 | $20.07 | $100,966.18 |
DisclosureSEC source: 0001415889-25-012031 · form4-05052025_100540.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 992,658 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 17:09 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 330 | $16.72 | $5,517.86 |
DisclosureSEC source: 0001415889-25-011213 · form4-04232025_090427.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 997,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.63 to $16.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 17:09 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,670 | $16.03 | $74,847.96 |
DisclosureSEC source: 0001415889-25-011213 · form4-04232025_090427.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 998,018 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.43 to $16.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 17:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $20.61 | $257,575.00 |
DisclosureSEC source: 0001415889-25-008790 · form4-03212025_090300.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,002,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.23 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 17:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 171,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003514 · form4-02102025_100234.xml · derivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 171,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 16:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 847 | $30.00 | $25,412.54 |
DisclosureSEC source: 0001415889-24-025504 · form4-10222024_081010.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,015,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,589 | $28.52 | $102,357.92 |
DisclosureSEC source: 0001415889-24-024992 · form4-10112024_121044.xml · nonDerivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,016,035 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $28.50 to $28.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 34,289 | $28.12 | $964,203.25 |
DisclosureSEC source: 0001415889-24-024992 · form4-10112024_121044.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,019,624 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 100 | $28.51 | $2,851.00 |
DisclosureSEC source: 0001415889-24-024992 · form4-10112024_121044.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,053,913 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 13,167 | $27.96 | $368,173.02 |
DisclosureSEC source: 0001415889-24-024992 · form4-10112024_121044.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,054,013 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 18:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,707 | $27.61 | $74,727.01 |
DisclosureSEC source: 0001415889-24-024902 · form4-10082024_101021.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,067,180 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 18:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,522 | $27.51 | $206,936.99 |
DisclosureSEC source: 0001415889-24-024902 · form4-10082024_101021.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,069,887 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 18:47 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 527 | $27.54 | $14,512.10 |
DisclosureSEC source: 0001415889-24-024672 · form4-10032024_101013.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,077,409 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 17:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 50 | $23.08 | $1,154.00 |
DisclosureSEC source: 0001415889-24-022704 · form4-09032024_090954.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,077,936 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 17:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 11,950 | $22.48 | $268,687.39 |
DisclosureSEC source: 0001415889-24-022704 · form4-09032024_090954.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,077,986 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.0729 to $23.0525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 19:26 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,099 | $27.56 | $85,399.45 |
DisclosureSEC source: 0001415889-24-020688 · form4-08022024_110826.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,089,936 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 19:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 203 | $27.43 | $5,568.96 |
DisclosureSEC source: 0001415889-24-020476 · form4-07312024_110752.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,093,035 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.3814 to $27.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 19:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 11,797 | $26.69 | $314,808.84 |
DisclosureSEC source: 0001415889-24-020476 · form4-07312024_110752.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,093,238 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.3755 to $27.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,000 | $22.89 | $274,736.40 |
DisclosureSEC source: 0001415889-24-019202 · form4-07032024_080732.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,105,035 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.6459 to $23.635. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. Read SEC document |
| May 29, 2024 Filed May 31, 2024 16:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-015031 · form4-05312024_080541.xml · derivative · entry 5 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 29, 2024 Filed May 31, 2024 16:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,123 | $22.52 | $47,812.51 |
DisclosureSEC source: 0001415889-24-015031 · form4-05312024_080541.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.2051 to $22.7331. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 29, 2024 Filed May 31, 2024 16:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 9,877 | $21.56 | $212,987.63 |
DisclosureSEC source: 0001415889-24-015031 · form4-05312024_080541.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,123 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.2024 to $22.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 29, 2024 Filed May 31, 2024 16:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-015031 · form4-05312024_080541.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 29, 2024 Filed May 1, 2024 19:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-011915 · form4-05012024_110500.xml · derivative · entry 5 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 29, 2024 Filed May 1, 2024 19:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,013 | $18.48 | $18,722.57 |
DisclosureSEC source: 0001415889-24-011915 · form4-05012024_110500.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $18.37 to $18.5795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.